Primary Sclerosing Cholangitis and Cholangiocarcinoma
The DOI matches its Crossref record.
Abstract
Primary sclerosing cholangitis (PSC), a cholestatic liver disease characterized by fibrosing inflammatory damage of the biliary tree, is a risk factor for cholangiocarcinoma (CCA). Indeed, the prevalence of CCA in patients with PSC ranges from 7 to 13%. The major challenges of CCA in PSC patients relate to lack of methods for early diagnosis and the absence of effective treatment. Early diagnosis of CCA in PSC is delayed because its clinical presentation can mimic benign dominant biliary strictures. Moreover, biliary and serum tests to diagnose development of CCA in PSC are limiting, although the use of advanced cytologic techniques for aneuploidy and chromosomal aberrations are promising in this regard. As a result, current therapies do not extend survival with the exception of protocol liver transplantation available to a selected group of patients. Future studies should emphasize deciphering the sequence of events that transform the inflammatory changes of the biliary tree to cancer. Only then will chemoprevention, early diagnosis, and therapy of CCA in patients with PSC improve.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“Distinguishing benign from malignant changes in PSC by imaging modalities like US, CT, MRCP/MRI as well as ERCP, is equally difficult [104,106].”
BackgroundInfluentialDiagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Self-citationWelzel, T. M., Graubard, B. I., El–Serag, H. B., Shaib, Y. H., Hsing, A. W., Davila, J. A., & McGlynn, K. A. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.020 · Cited by 514
Bile acids as endogenous etiologic agents in gastrointestinal cancer
Bernstein, H., Bernstein, C., Payne, C. M., & Dvorak, K. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.3329 · Cited by 340
Liau, J.-Y., Tsai, J.-H., Yuan, R.-H., Chang, C.-N., Lee, H.-J., & Jeng, Y.-M. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.241 · Cited by 265
Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome
Floreani, A., Rizzotto, E. R., Ferrara, F., Carderi, I., Caroli, D., Blasone, L., & Baldo, V. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41841.x · Cited by 230
Welzel, T. M., Mellemkjaer, L., Gloria, G., Sakoda, L. C., Hsing, A. W., Ghormli, L. E., Olsen, J. H., & McGlynn, K. A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22283 · Cited by 195
“Chronic inflammation of the bile ducts as well as cholestasis may contribute to the malignant transformation of the biliary epithelium in patients with PSC, and the prevalence of ICC in patients with PSC ranges from 7–13%.(18)”
BackgroundEnhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
Vesterhus, M., Hov, J. R., Holm, A., Schrumpf, E., Nygård, S., Godang, K., Andersen, I. M., Næss, S., Thorburn, D., Saffioti, F., et al. (2015) · Hepatology · doi:10.1002/hep.27825 · Cited by 138
“Albumin, g/L, median (range)* 40 (22-50) 34 (15-46) <0.”
InfluentialInterpreting serological tests in diagnosing autoimmune liver diseases
Invernizzi, P., Lleo, A., & Podda, M. (2007) · Seminars in Liver Disease · doi:10.1055/s-2007-979469 · Cited by 107
de Vries, E. M. G., Färkkilä, M., Milkiewicz, P., Hov, J. R., Eksteen, B., Thorburn, D., Chazouillères, O., Pares, A., Nygård, S., Gilja, O. H., et al. (2017) · Liver International · doi:10.1111/liv.13402 · Cited by 83
“question of whether the association between ELF test and CCA in PSC reflects more advanced disease in these patients or results from the excessive fibrotic response in the surrounding tissue of the “scirrhous” type of CCA often found in PSC, potentially an early risk sign for CCA.[20,21] Dedicated analyses seem warran…”
BackgroundWannhoff, A., Brune, M., Knierim, J., Weiss, K. H., Rupp, C., & Gotthardt, D. N. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15146 · Cited by 17
Metadata
- Authors
- Lazaridis, K. N., & Gores, G. J.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2006
- Volume
- 26
- Issue
- 01
- Pages
- 042-051
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W1983134951
- Cited by
- 136
- References
- 0
- FWCI
- 9.24
- Type
- journal article
- Language
- de
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.